Measles control--can measles virus inhibitors make a difference?

A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine (2011) 1.18

Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine (2011) 1.12

Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol (2013) 0.96

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem (2012) 0.90

Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J Virol (2013) 0.87

Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine (2012) 0.86

Synergizing vaccinations with therapeutics for measles eradication. Expert Opin Drug Discov (2013) 0.83

The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Front Microbiol (2015) 0.79

A pioneering countermeasure against measles virus. Ann Transl Med (2015) 0.75

Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex. Viruses (2016) 0.75

Retracted Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (1998) 36.93

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62

The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71

Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27

A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med (2002) 7.14

SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73

Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet (2007) 4.21

Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1998) 4.19

Measles elimination in the Americas. Evolving strategies. JAMA (1996) 3.82

Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71

Retraction of an interpretation. Lancet (2004) 3.55

Measles in Europe: an epidemiological assessment. Lancet (2009) 3.49

Measles endemicity in insular populations: critical community size and its evolutionary implication. J Theor Biol (1966) 3.18

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A (1996) 3.07

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89

Update: measles--United States, January-July 2008. MMWR Morb Mortal Wkly Rep (2008) 2.55

The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis (2004) 2.42

Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis (1994) 2.30

Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol (2001) 2.29

Global measles elimination. Nat Rev Microbiol (2006) 2.21

Vitamin A supplements and mortality related to measles: a randomised clinical trial. Br Med J (Clin Res Ed) (1987) 2.12

Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology (1995) 2.11

Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog (2007) 2.09

Modelling the persistence of measles. Trends Microbiol (1997) 1.98

Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A (2004) 1.84

Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83

Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol (2000) 1.72

Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 1.70

Polio eradication. Looking for a little luck. Science (2009) 1.55

Ribavirin: a clinical overview. Eur J Epidemiol (1986) 1.51

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine (2001) 1.39

Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother (1992) 1.24

Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother (2007) 1.24

Morbilliviruses and human disease. J Pathol (2006) 1.22

A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18

Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17

Vitamin A supplementation: implications for morbidity and mortality in children. J Infect Dis (2000) 1.16

Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis (2001) 1.16

Measles vaccines and the potential for worldwide eradication of measles. Pediatrics (2004) 1.16

Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol (1999) 1.14

Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platensis. J Nat Prod (1996) 1.12

Measles eradication: is it in our future? Am J Public Health (2000) 1.12

Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine (2000) 1.11

Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08

Potential antiviral agents. Carbobenzoxy di- and tripeptides active against measles and herpes viruses. J Med Chem (1968) 1.08

The measles virus replication cycle. Curr Top Microbiol Immunol (2009) 1.08

Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis (1999) 1.07

Update: global measles control and mortality reduction--worldwide, 1991-2001. MMWR Morb Mortal Wkly Rep (2003) 1.04

Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem (2008) 1.03

Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr (2005) 1.02

Further evaluation of Rwandan medicinal plant extracts for their antimicrobial and antiviral activities. J Ethnopharmacol (2002) 1.01

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorg Med Chem Lett (2007) 1.00

Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev Vaccines (2008) 0.99

Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res (1993) 0.99

Progress in global measles control and mortality reduction, 2000-2007. MMWR Morb Mortal Wkly Rep (2008) 0.98

Antiviral activities of biflavonoids. Planta Med (1999) 0.96

Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. J Gen Virol (1989) 0.93

Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol (2003) 0.93

Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues. Antivir Chem Chemother (2001) 0.92

The sense of the helix of paramyxovirus nucleocapsids. J Mol Biol (1972) 0.91

MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines (2004) 0.91

ADEM: literature review and case report of acute psychosis presentation. Pediatr Neurol (2000) 0.91

Inhibitors of measles virus. Antivir Chem Chemother (2004) 0.91

Ribavirin response in measles pneumonia. J Infect (1990) 0.89

Measles virus: evidence of an association with Hodgkin's disease. Br J Cancer (2004) 0.88

Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol (2003) 0.88

Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob Agents Chemother (2000) 0.88

Antiviral activity of carbobenzosy di- and tripeptides on measles virus. Appl Microbiol (1968) 0.87

Polio--new challenges in 2006. J Clin Virol (2006) 0.85

Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol (2009) 0.85

New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents. J Med Chem (1992) 0.84

Screening extracts of Zanthoxylum chalybeum and Warburgia ugandensis for activity against measles virus (Swartz and Edmonston strains) in vitro. Afr Health Sci (2002) 0.84

Measles vaccination: new strategies and formulations. Expert Rev Vaccines (2008) 0.84

Experience in global measles control, 1990-2001. J Infect Dis (2003) 0.84

Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology (1995) 0.84

Measles in Europe--there is room for improvement. Lancet (2009) 0.84

Measles once again endemic in the United Kingdom. Euro Surveill (2008) 0.84

Inhibitory potential of Crotalus durissus terrificus venom on measles virus growth. Toxicon (2003) 0.83

Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J Med Chem (1992) 0.83

Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J (1996) 0.83

Antisense-mediated resistance to measles virus infection in HeLa cells. J Infect Dis (1997) 0.82

Traditional dietary additives of the Maasai are antiviral against the measles virus. J Ethnopharmacol (2007) 0.82

A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res (1998) 0.82

Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother (2002) 0.81

Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res (1995) 0.81

The pathogenesis of measles revisited. Pediatr Infect Dis J (2008) 0.80

Fulminating adult-onset subacute sclerosing panencephalitis in a 49-year-old man. Arch Neurol (2003) 0.80

Association of measles virus with rheumatoid arthritis. J Rheumatol (2009) 0.80

3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties. J Med Chem (1995) 0.79

New candidate virus in association with Hodgkin's disease. Leuk Lymphoma (2003) 0.79

Multiple sclerosis and measles virus. Jpn J Infect Dis (1999) 0.78

[Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin]. Rev Neurol (2006) 0.78

5'-Fluoro-5'-deoxyaristeromycin. Bioorg Med Chem Lett (2007) 0.78

in vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4,5-e]diazepine ring system. Bioorg Med Chem Lett (2002) 0.78

Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J (1993) 0.78

Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res (2009) 0.78

Inhibition effect of shengma-gegen-tang on measles virus in Vero cells and human peripheral blood mononuclear cells. Am J Chin Med (1997) 0.78

Spicebush. A Cherokee remedy for the measles. N C Med J (1996) 0.78

Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) 2.50

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science (2004) 2.18

Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem (2004) 2.09

Functional interaction between paramyxovirus fusion and attachment proteins. J Biol Chem (2008) 1.78

Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chem Biol (2012) 1.60

Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56

Probing the spatial organization of measles virus fusion complexes. J Virol (2009) 1.50

EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs (2005) 1.48

Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43

Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42

Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol (2010) 1.37

The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs. Proc Natl Acad Sci U S A (2004) 1.37

Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther (2006) 1.33

Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33

Highly active anticancer curcumin analogues. Adv Exp Med Biol (2007) 1.27

Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26

Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26

Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.24

Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother (2007) 1.24

EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (2008) 1.23

Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20

Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci (2003) 1.20

Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci (2010) 1.18

Development of a unique small molecule modulator of CXCR4. PLoS One (2012) 1.18

A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18

Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One (2011) 1.18

Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol (2011) 1.17

Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target (2008) 1.17

Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17

The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle (2005) 1.16

Paclitaxel binding to human and murine MD-2. J Biol Chem (2008) 1.13

Discovery of small molecule CXCR4 antagonists. J Med Chem (2007) 1.12

Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem (2006) 1.11

Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08

Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem (2010) 1.08

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08

Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther (2007) 1.07

Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother (2009) 1.07

Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett (2009) 1.06

Facial symmetry in protein self-assembly. J Am Chem Soc (2008) 1.05

Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge. J Virol (2007) 1.05

A stereoelectronic effect on turn formation due to proline substitution in elastin-mimetic polypeptides. J Am Chem Soc (2005) 1.03

The T-Taxol conformation. J Med Chem (2006) 1.03

Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem (2008) 1.03

High-throughput screening-based identification of paramyxovirus inhibitors. J Biomol Screen (2008) 1.02

Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci (2011) 1.01

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorg Med Chem Lett (2007) 1.00

Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Cancer (2009) 0.99

The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem (2009) 0.99

Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol (2011) 0.98

Cross-strand pairing and amyloid assembly. Biochemistry (2008) 0.97

3-Fluoropiperidines and N-methyl-3-fluoropiperidinium salts: the persistence of axial fluorine. Chemistry (2005) 0.96

Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation. ACS Med Chem Lett (2011) 0.95

Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol (2010) 0.95

Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett (2013) 0.94

T-Taxol and the electron crystallographic density in beta-tubulin. Org Lett (2005) 0.93

Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol (Camb) (2012) 0.93

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J Pharmacol Exp Ther (2010) 0.92

Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Mol Pharmacol (2012) 0.92

Alpha-turn mimetics: short peptide alpha-helices composed of cyclic metallopentapeptide modules. J Am Chem Soc (2004) 0.92

Bridging converts a noncytotoxic nor-paclitaxel derivative to a cytotoxic analogue by constraining it to the T-Taxol conformation. Org Lett (2006) 0.91

The NH---FC dipole orientation effect for pendant exocyclic CH(2)F. Org Lett (2002) 0.91

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem (2012) 0.90

The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle (2009) 0.90

Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem (2012) 0.89

Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. J Med Chem (2006) 0.89

Design, synthesis, and bioactivity of simplified paclitaxel analogs based on the T-Taxol bioactive conformation. Bioorg Med Chem (2006) 0.88

Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition. Integr Biol (Camb) (2012) 0.88

Dictyostatin flexibility bridges conformations in solution and in the β-tubulin taxane binding site. J Am Chem Soc (2011) 0.88

The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr Med Chem Anticancer Agents (2002) 0.88

Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance. Biochemistry (2008) 0.87

Relationship among ligand conformations in solution, in the solid state, and at the Hsp90 binding site: geldanamycin and radicicol. J Am Chem Soc (2007) 0.87

Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993). Cancer Chemother Pharmacol (2014) 0.87

Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem (2009) 0.86

Asymmetric synthesis of host-directed inhibitors of myxoviruses. Beilstein J Org Chem (2013) 0.85

Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors. ChemMedChem (2013) 0.85

The discodermolide hairpin structure flows from conformationally stable modular motifs. J Med Chem (2010) 0.85

Studies toward the synthesis of oximidines I and II. Org Lett (2003) 0.85

Dynamics and fluidity of amyloid fibrils: a model of fibrous protein aggregates. J Am Chem Soc (2002) 0.85

Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorg Med Chem (2008) 0.85

Discovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency. ChemMedChem (2011) 0.84

Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. J Med Chem (2005) 0.84

Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. Curr Cancer Drug Targets (2014) 0.84

Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis. Cell Tissue Res (2014) 0.83

Discovery of a new class of liver receptor homolog-1 (LRH-1) antagonists: virtual screening, synthesis and biological evaluation. ChemMedChem (2012) 0.83

Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Mol Brain (2008) 0.82

Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. J Med Chem (2010) 0.82

Regulation of GluA1 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor function by protein kinase C at serine-818 and threonine-840. Mol Pharmacol (2014) 0.81

Organocuprate conjugate addition: the square-planar "CuIII" intermediate. J Am Chem Soc (2007) 0.81

Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem (2008) 0.81

Design, synthesis and biological evaluation of bridged epothilone D analogues. Org Biomol Chem (2008) 0.81

Design and synthesis of C6-C8 bridged epothilone A. Org Lett (2008) 0.81

Conformations of laulimalide in DMSO-d6. J Am Chem Soc (2005) 0.81

The tubulin-bound conformation of paclitaxel: T-taxol vs "PTX-NY". J Nat Prod (2009) 0.81

Dicubyl disulfide. J Am Chem Soc (2002) 0.81

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists. J Med Chem (2013) 0.81

Cyclostreptin and microtubules: is a low-affinity binding site required? Chembiochem (2010) 0.80

Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. J Med Chem (2013) 0.80

Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure. Chembiochem (2014) 0.80